Skip to main content
. Author manuscript; available in PMC: 2022 Oct 1.
Published in final edited form as: Trends Pharmacol Sci. 2021 Aug 10;42(10):829–844. doi: 10.1016/j.tips.2021.07.002

Table 1.

Summary of clinical cases reporting the use of ascorbate in G6PDdef.

Hemolytic
Trigger
Dose Treatment Dose Response to Trigger Type of Study References
Ascorbate 80g/day, IV Blood transfusion X X X X X case study [118]
Ascorbate 40g/3x/week, IV + 20-40g/daily/oral X X X case study [119]
Increased to 80g/3x/week, IV
Ascorbate 30g/day, IV Blood transfusion 8 days X X case study [120]
60g/day, IV
Fava Beans Ascorbate ~10 beans X case study [121]
250-500mg/day, oral
Ascorbate 4-6g/6hr, oral Blood transfusion X X case study [122]
Ascorbate 30g/day, IV Blood transfusion X X X X case study [123]
Ascorbate 75g/day, IV Blood transfusion X X X X case study [124]
Ascorbate 2g/day, IV - X X case study [125]
Rasburicase 6mg Ascorbate 5g/6hrs, IV X X X case study [46]
Blood transfusion
Rasburicase 6mg Ascorbate 1g/day, oral X X X case study [47]
Blood transfusion
Chloroquine + Covid-19 600mg/day Ascorbate 1g/4x/day X X case study [23]
Blood transfusion
Fava Beans Ciprofloxacin Acetaminophen 500mg/2x/daily
1000mg/3x/daily
Ascorbate 1g/4x/day X X X X case study [48]
Blood transfusion
Hemolysis/Anemia Dark Urine Methemoglobinemia Respiratory Distress /↓O2 Death Renal Failure